X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs AJANTA PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA AJANTA PHARMA GLENMARK PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 19.8 19.8 100.0% View Chart
P/BV x 3.5 4.5 78.0% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 GLENMARK PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
AJANTA PHARMA
Mar-18
GLENMARK PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs9931,818 54.6%   
Low Rs7291,106 65.9%   
Sales per share (Unadj.) Rs325.5239.5 135.9%  
Earnings per share (Unadj.) Rs39.352.8 74.4%  
Cash flow per share (Unadj.) Rs48.759.5 81.8%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs159.2230.0 69.2%  
Shares outstanding (eoy) m282.1788.77 317.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.66.1 43.3%   
Avg P/E ratio x21.927.7 79.1%  
P/CF ratio (eoy) x17.724.6 72.0%  
Price / Book Value ratio x5.46.4 85.1%  
Dividend payout %5.10-   
Avg Mkt Cap Rs m242,991129,782 187.2%   
No. of employees `00013.06.8 190.8%   
Total wages/salary Rs m16,4083,765 435.8%   
Avg. sales/employee Rs Th7,083.93,128.4 226.4%   
Avg. wages/employee Rs Th1,265.4554.0 228.4%   
Avg. net profit/employee Rs Th855.1689.7 124.0%   
INCOME DATA
Net Sales Rs m91,85721,258 432.1%  
Other income Rs m374242 154.7%   
Total revenues Rs m92,23021,499 429.0%   
Gross profit Rs m20,3676,584 309.3%  
Depreciation Rs m2,644596 443.6%   
Interest Rs m2,3734 57,882.9%   
Profit before tax Rs m15,7246,226 252.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8271,539 248.6%   
Profit after tax Rs m11,0884,686 236.6%  
Gross profit margin %22.231.0 71.6%  
Effective tax rate %24.324.7 98.4%   
Net profit margin %12.122.0 54.8%  
BALANCE SHEET DATA
Current assets Rs m68,74612,236 561.8%   
Current liabilities Rs m27,0273,461 781.0%   
Net working cap to sales %45.441.3 110.0%  
Current ratio x2.53.5 71.9%  
Inventory Days Days8560 141.2%  
Debtors Days Days9684 113.1%  
Net fixed assets Rs m24,13211,140 216.6%   
Share capital Rs m282177 159.5%   
"Free" reserves Rs m44,64320,237 220.6%   
Net worth Rs m44,92520,414 220.1%   
Long term debt Rs m45,36310 449,142.6%   
Total assets Rs m117,63924,486 480.4%  
Interest coverage x7.61,519.4 0.5%   
Debt to equity ratio x1.00 204,087.1%  
Sales to assets ratio x0.80.9 89.9%   
Return on assets %11.419.2 59.7%  
Return on equity %24.723.0 107.5%  
Return on capital %19.130.5 62.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15211,667 481.3%   
Fx outflow Rs m8,0841,616 500.4%   
Net fx Rs m48,06810,052 478.2%   
CASH FLOW
From Operations Rs m6,5742,854 230.3%  
From Investments Rs m-7,124-2,604 273.5%  
From Financial Activity Rs m5,432-2 -271,575.0%  
Net Cashflow Rs m1,992248 803.1%  

Share Holding

Indian Promoters % 48.3 73.8 65.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 1.6 445.2%  
FIIs % 34.4 7.6 452.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.0 61.8%  
Shareholders   56,727 20,968 270.5%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  CADILA HEALTHCARE  AUROBINDO PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Pharma & Realty Stocks Gain(09:30 am)

Asian share markets are mixed today. The Nikkei 225 is flat while the Hang Seng is down 0.1%. The Shanghai Composite is trading down by 1.1%.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 20, 2018 10:49 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS